GlassScriptPhysician profile
Charles Carey
NPI 1821290123
$1,638.44
in general payments reported to CMS, 2019-2025
27 companies · $51.28 in 2025
The $51.28 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $613 · 2023: $524 · 2024: $325 · 2025: $51.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.15 | 2021-2023 | |
| Pfizer INC. | $188.82 | 2022-2025 | |
| Novo Nordisk INC | $173.20 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $107.74 | 2021-2024 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $76.43 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $73.73 | 2022-2023 | Rexulti, Abilify Maintena |
| Harmony Biosciences LLC | $67.54 | 2023 | Wakix |
| Lilly USA, LLC | $50.06 | 2022-2024 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $45.73 | 2023 | Sunosi, Auvelity |
| Exact Sciences Corporation | $32.69 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $29.57 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $29.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.99 | 2024 | Ultomiris |
| Daiichi Sankyo INC. | $23.69 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $20.39 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.39 | 2024 | Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $18.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.46 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.58 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.76 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2022 | |
| Amgen INC. | $14.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.07 | 2021 | |
| Ibsa Pharma INC. | $13.18 | 2023 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.